
Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab
Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.




























